Equities

SMS Pharmaceuticals Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
SMSPHARMA:NSI

SMS Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)337.15
  • Today's Change-15.55 / -4.41%
  • Shares traded238.03k
  • 1 Year change+65.27%
  • Beta1.3109
Data delayed at least 15 minutes, as of Feb 13 2026 10:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

SMS Pharmaceuticals Limited is an India-based pharmaceutical manufacturing company. The Company is engaged in the business of manufacturing active pharma ingredients and their intermediates. Its product categories include anti-ulcer, anti-inflammatory, anti-migraine, ant-diabetic, anti-coagulant, anti-viral, anti-retroviral, anti-psychotic, and others. The Company products include ranitidine, famotidine, pantoprazole sodium, itraconazole, lanoconazole, luliconazole, ibuprofen, Dex ibuprofen, fenoprofen calcium, sumatriptan, almotriptan, zolmitriptan, rizatriptan, Ele triptan, vildagliptin, sitagliptin, rosiglitazone, empagliflozin, dapagliflozin, tenofovir, dolutegravir, raltegravir, lamivudine, efavirenz, apixaban, rivaroxaban, levetiracetam, perampanel, lamotrigine, penciclovir, valaciclovir, and others. The Company has manufacturing facilities at Bachupally, Hyderabad, Telangana and also at Kandivalasa Village, Poosapatirega Mandal, Vijayanagaram District, Andhra Pradesh.

  • Revenue in INR (TTM)8.97bn
  • Net income in INR895.91m
  • Incorporated1987
  • Employees1.47k
  • Location
    SMS Pharmaceuticals LtdPlot No.72,H. No.8-2-334/3 & 4 Road No.5, Opp. SBIHYDERABAD 500034IndiaIND
  • Phone+91 4 066288888
  • Fax+91 4 023551401
  • Websitehttps://smspharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Morepen Laboratories Ltd17.87bn994.48m21.12bn1.81k21.24--14.331.181.811.8132.65--------9,850,214.00--8.14--12.8133.7131.835.615.91--5.59----7.1716.2622.7328.5865.86--
Panacea Biotec Ltd6.04bn-72.40m21.44bn1.29k--2.5981.723.55-1.18-1.1898.44134.920.48361.388.674,681,039.00-0.608513.08-0.829119.6158.4748.06-1.2630.990.9785-14.330.02710.00-0.01320.5466-613.56--48.74--
IOL Chemicals and Pharmaceuticals Ltd16.47bn953.20m21.94bn2.89k23.00--14.271.333.253.25----------5,696,991.00--10.26--13.4234.4332.575.799.33--8.05--13.68-2.511.88-24.82-22.4921.615.92
Solara Active Pharma Sciences Ltd12.55bn-191.10m22.08bn1.78k----28.011.76-4.81-4.81330.32--------7,068,733.00---3.27---5.3551.7739.95-1.52-6.17--0.7946-----0.4003-0.5816100.10-65.75-31.71--
Bliss GVS Pharma Ltd8.68bn1.09bn23.04bn966.0021.39--15.652.6510.1810.1880.97--------8,986,598.00--6.04--7.5452.6546.3313.189.45--8.44--8.275.133.2711.72-2.825.180.00
Hikal Ltd16.99bn101.00m26.33bn2.06k259.882.2016.291.550.82160.8216137.8196.860.70652.014.598,239,573.000.424.780.60167.0055.4948.000.59455.710.54181.110.363914.834.214.2930.461.46-2.773.13
Unichem Laboratories Ltd22.14bn2.95bn26.43bn3.33k8.98--6.311.1941.7941.79314.32--------6,654,374.00---0.5598---0.697754.0655.0913.32-1.18--3.47----18.2513.85246.67---18.68--
Gufic BioSciences Ltd8.74bn569.19m31.04bn1.99k54.514.9236.573.555.685.6887.1062.940.73541.872.754,394,322.004.7910.277.3416.1155.4746.416.5210.481.063.130.36911.311.6316.69-19.1425.1513.6414.87
SMS Pharmaceuticals Ltd8.97bn895.91m31.57bn1.47k33.29--25.153.5210.1310.13101.51--------6,102,851.00--5.58--7.6632.5533.789.718.05--5.85--5.7210.3613.7038.7516.9723.629.86
Dishman Carbogen Amcis Ltd27.97bn1.19bn31.63bn1.11k26.64--7.061.137.577.57178.50--------25,287,880.00---0.7247---0.900584.9674.274.25-2.77--1.31----3.665.82102.11-54.07-11.91--
RPG Life Sciences Ltd6.74bn2.03bn32.66bn1.33k16.12--14.604.85122.51122.51407.37--------5,061,758.00--21.05--27.7864.3463.2830.0716.68--174.47--24.9212.2611.71109.0344.5827.3937.97
Orchid Pharma Ltd8.21bn522.57m33.70bn737.0064.462.6538.744.1010.3110.31162.05251.160.48931.583.9411,143,480.003.101.403.631.7239.8335.896.332.751.902.180.181--12.4813.768.13--104.06--
Aarti Drugs Ltd25.22bn2.03bn33.93bn1.28k16.84--12.741.3522.0722.07274.99--------19,639,960.00--9.09--14.3936.3522.098.038.08--7.00--6.07-5.605.74-1.903.5329.8514.87
Gujarat Themis Biosyn Ltd1.59bn477.88m34.02bn221.0071.20--58.7821.364.394.3914.62--------7,209,322.00--30.70--34.3762.7868.0329.9935.51--55.73-----11.2012.12-17.5615.55104.6124.95
Senores Pharmaceuticals Ltd5.89bn1.02bn36.09bn194.0034.97--27.756.1322.4122.41130.31--------30,336,080.00--------58.73--17.48----5.94----85.64--86.17------
Innova Captab Ltd14.97bn1.32bn38.85bn1.95k29.34--22.072.6023.1323.13261.52--------7,676,703.00--10.02--15.0036.2627.208.858.72--12.45----15.0227.2135.9535.69109.94--
Data as of Feb 13 2026. Currency figures normalised to SMS Pharmaceuticals Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

2.96%Per cent of shares held by top holders
HolderShares% Held
quant Money Managers Ltd.as of 30 Jan 20262.77m2.96%
American Century Investment Management, Inc.as of 05 Feb 2026881.000.00%
Motilal Oswal Asset Management Co. Ltd.as of 31 Dec 2025847.000.00%
Bandhan AMC Ltd.as of 31 Jan 2026358.000.00%
More ▼
Data from 31 Dec 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.